Relugolix

340 interactions 260 explained in plain English 125 cited references

Also sold as: Orgovyx Orgovyx®

About Relugolix

Relugolix is a gonadotropin-releasing hormone receptor antagonist used to treat advanced prostate cancer in adult men. Read the full Relugolix drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 2, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Dengue Tetravalent Vaccine, Live Levoketoconazole Measles Virus Vaccine, Live Mesoridazine Mumps Virus Vaccine, Live

22 Contraindicated 313 Major 5 Moderate

All (340) Contraindicated (22) Major (313) Moderate (5)

Major

Relugolix Olanzapine Explained Increased risk of QT interval prolongation Details Relugolix Ondansetron Explained Increased risk of QT interval prolongation Details Relugolix Osilodrostat Isturisa Explained Increased risk of QT interval prolongation Details Relugolix Osimertinib Tagrisso Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Relugolix Oxaliplatin Explained Increased risk of QT interval prolongation Details Relugolix Paliperidone Erzofri Explained Increased risk of QT interval prolongation Details Relugolix Panobinostat Farydak Explained Increased risk of QT interval prolongation Details Relugolix Papaverine Pavacot® Explained Increased risk of QT interval prolongation Details Relugolix Paroxetine Paxil Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Relugolix Pasireotide Signifor Explained Increased risk of QT interval prolongation Details Relugolix Pazopanib Votrient Explained Increased risk of QT interval prolongation Details Relugolix Pentamidine NebuPent Explained Increased risk of QT interval prolongation Details Relugolix Perphenazine Explained Increased risk of QT interval prolongation Details Relugolix Pexidartinib Turalio Explained Increased relugolix exposure Details Relugolix Phenytoin Dilantin Explained Reduced relugolix exposure and reduced efficacy of relugolix Details Relugolix Pibrentasvir Explained Increased relugolix exposure Details Relugolix Pipamperone Explained Increased risk of QT interval prolongation Details Relugolix Piperine Explained Increased relugolix exposure Details Relugolix Pirtobrutinib Jaypirca Explained Increased relugolix exposure Details Relugolix Pitolisant Wakix Explained Increased risk of QT interval prolongation Details Relugolix Ponesimod Ponvory Explained Increased risk of QT interval prolongation Details Relugolix Posaconazole Noxafil Explained Increased risk of QT interval prolongation Details Relugolix Probucol Explained Increased risk of QT interval prolongation Details Relugolix Procainamide Procan® Explained Increased risk of QT interval prolongation Details Relugolix Prochlorperazine Explained Increased risk of QT interval prolongation Details Relugolix Promethazine Phenadoz Explained Increased risk of QT interval prolongation Details Relugolix Propafenone Rythmol Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Relugolix Protriptyline Explained Increased risk of QT interval prolongation Details Relugolix Quercetin Explained Increased relugolix exposure Details Relugolix Quetiapine Seroquel Explained Increased risk of QT interval prolongation Details Relugolix Quinidine Cardioquin® Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Relugolix Quinine Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Relugolix Ribociclib Kisqali Explained Increased risk of QT interval prolongation Details Relugolix Rifampin Rifadin Explained Altered relugolix exposure, an increased risk of relugolix-related adverse reactions and reduced efficacy of relugolix Details Relugolix Rilpivirine Edurant Explained Increased risk of QT interval prolongation Details Relugolix Risperidone Perseris Explained Increased risk of QT interval prolongation Details Relugolix Ritonavir Norvir Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Relugolix Rolapitant Varubi Explained Increased relugolix exposure Details Relugolix Rotavirus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Relugolix Rucaparib Rubraca Explained Increased relugolix exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.